ImmuPharma plc (LON:IMM - Get Free Report) rose 4.6% on Thursday . The stock traded as high as GBX 11.30 ($0.15) and last traded at GBX 11.30 ($0.15). Approximately 26,234,178 shares changed hands during trading, an increase of 230% from the average daily volume of 7,944,629 shares. The stock had previously closed at GBX 10.80 ($0.15).
ImmuPharma Stock Performance
The firm has a market capitalization of £64.94 million, a PE ratio of -1,460.11 and a beta of 1.53. The firm has a fifty day moving average of GBX 2.72 and a 200 day moving average of GBX 2.82.
ImmuPharma (LON:IMM - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Research analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.
About ImmuPharma
(
Get Free Report)
ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ImmuPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuPharma wasn't on the list.
While ImmuPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
